<DOC>
	<DOCNO>NCT00264498</DOCNO>
	<brief_summary>The primary objective demonstrate chemotherapy na√Øve patient advance ( Stage IIIB IV ) NSCLC ECOG PS 2 non-inferiority progression free survival ( PFS ) ZD1839 compare gemcitabine/carboplatin .</brief_summary>
	<brief_title>Phase II Iressa &amp; Carbo/Gem NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Advanced Non Small cell Lung Cell Lung cancer Never receive chemotherapy Up 50 % waking hour Spread lung cancer brain Low level white blood cell Radiotherapy within 4 week Patients enter study , initiated 2004 , significance predictive factor smoke history , adenocarcinoma histology mutation status describe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>